Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.45 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2990886 | 0.84 | CA1 (0.46) | PRMT1CYP19A1MAOAMAOBCA1 | |
| SCHEMBL29413066 | 0.83 | PRMT1 (0.44) | PRMT1CYP19A1MAOAMAOBCA1 | |
| SCHEMBL4428520 | 0.80 | ALDH1A1 (0.43) | PRMT1CYP19A1CCR2ALDH1A1TSHR | |
| SCHEMBL1816198 | 0.80 | PRMT1 (0.43) | PRMT1CYP19A1MAOAMAOBCA1 | |
| SCHEMBL4428799 | 0.80 | CYP19A1 (0.47) | PRMT1CYP19A1MAOAMAOBCA1 | |
| SCHEMBL17327582 | 0.80 | IKBKB (0.44) | PRMT1CA1CA2CYP2C19CA9 | |
| SCHEMBL14873483 | 0.79 | CYP19A1 (0.44) | PRMT1CYP19A1MAOAMAOBCA1 | |
| SCHEMBL603914 | 0.79 | CA1 (0.62) | CYP19A1CA1CA2CA9ALDH1A1 | |
| SCHEMBL1937569 | 0.79 | CA2 (0.56) | PRMT1CYP19A1MAOAMAOBCA1 | |
| Hydrochloric Acid SCHEMBL14861689 | 0.78 | CYP19A1 (0.43) | PRMT1CYP19A1MAOAMAOBCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130338147-A1 | 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-12-19 | — | — | US | disclosed |
| US-8507498-B2 | 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-08-13 | — | — | US | disclosed |
| US-8507498-B2 | 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-08-13 | — | — | US | disclosed |
| US-8466201-B2 | Potassium ion channel modulators and uses thereof | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2013-06-18 | — | — | US | disclosed |
| EP-2231594-B1 | POTASSIUM ION CHANNEL MODULATORS AND USES THEREOF | UNIV RAMOT (IL) | 2013-03-27 | — | — | EP | disclosed |
| EP-2137166-B1 | 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2012-05-30 | — | — | EP | disclosed |
| US-20120065270-A1 | POTASSIUM ION CHANNEL MODULATORS AND USES THEREOF | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2012-03-15 | — | — | US | disclosed |
| US-20110306602-A1 | 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2011-12-15 | — | — | US | disclosed |
| US-20110306602-A1 | 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2011-12-15 | — | — | US | disclosed |
| US-20110306602-A1 | 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2011-12-15 | — | — | US | disclosed |
| EP-2231594-A2 | POTASSIUM ION CHANNEL MODULATORS AND USES THEREOF | Ramot at Tel-Aviv University Ltd (IL) | 2010-09-29 | — | — | EP | disclosed |
| EP-2137166-A1 | 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | Ingenium Pharmaceuticals GmbH (DE) | 2009-12-30 | — | — | EP | disclosed |
| WO-2009071947-A2 | POTASSIUM ION CHANNEL MODULATORS & USES THEREOF | LECTUS THERAPEUTICS LIMITED (GB) | 2009-06-11 | — | — | WO | disclosed |
| WO-2008129080-A1 | 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008129080-A1 | 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338147-A1 | 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | CDK2, CDK6, CDK5 | PRMT1 1495/4885CYP19A1 2988/4885MAOA 3269/4885 |
| US-20110306602-A1 | 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | CDK6, CDK2, CDK1 | PRMT1 1557/4885CYP19A1 2527/4885MAOA 2866/4885 |
| US-20120065270-A1 | POTASSIUM ION CHANNEL MODULATORS AND USES THEREOF | KCNN3, SCN2B, SCN1B | PRMT1 2062/4885CYP19A1 2369/4885MAOA 3209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.